开辟道路:传统药物化学灵感为合理的格拉姆阴性药物设计
Alexis M Stoorza1, Adam S Duerfeldt1
1Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.
Journal of medicinal chemistry
|December 22, 2023
概括
开发针对格拉姆阴性细菌的小分子药物是很困难的,因为它们的保护性细胞包裹. 需要新的策略来改善药物透和积累,以获得有效的治疗方法.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 开发有效的小分子治疗药物来对抗格拉姆阴性病原体是具有挑战性的.
- 细菌细胞外,特别是外膜和排泄,作为重要的透性障碍.
- 由于这些障碍,许多生化活性化合物无法表现出全细胞活性.
研究的目的:
- 为了应对设计小分子药物用于格兰阴性细菌的挑战.
- 为优化细菌细胞透和细胞内积累的小分子提出指导原则.
- 倡导药物化学的方法与真核生物药物设计中使用的方法相似.
主要方法:
- 这种观点综合了关于细菌细胞外和药物设计原则的现有知识.
- 它与用于真核生物药物开发的传统药物化学策略有相似之处.
- 该研究提出了基于这些比较的行动呼吁.
主要成果:
- 鉴定了细菌细胞包裹,包括外膜和排泄,作为药物疗效的关键障碍.
- 突出了加强小分子透和细胞内积累在格拉姆阴性细菌中的战略的关键需求.
- 强调了适应真核生物药物设计原则以发现抗菌药物的潜力.
结论:
- 克服格兰阴性细菌的透性障碍对于开发新疗法至关重要.
- 合理优化小分子对于高效的透和积累至关重要.
- 以真核生物药物设计为灵感的范式转变可能会彻底改变新型抗菌剂的发现.
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Structure-Activity Relationships and Drug Design
727
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
727
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Antibiotic Selection
53.9K
Overview
53.9K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
208
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
208


